Innovative NeuroTechnologies, Inc. (INT) is a development-stage biotechnology company operating in a “virtual mode” that is pursuing novel biologically-based and disease-modifying therapeutic solutions for a spectrum of neurodegenerative disorders referred to as tauopathies. Dysregulation of the Tau protein is the result of some genetic diseases that currently have no effective treatments, and is largely responsible for the onset of Alzheimer’s disease (AD). By focusing on Tau, we are developing a pipeline of disease-modifying biotherapeutic candidates or products to prevent, delay, or mitigate the underlying dementia or cognitive deficits observed in AD and other related neurodegenerative tauopathies, including:
Frontotemporal dementia (FTD) or Pick’s disease,
Chronic traumatic encephalopathy (CTE) or dementia pugilistica,
Progressive supranuclear palsy (PSP),
Corticobasal degeneration (CBD), and
Familial form of frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).